Molecular Hematology and Coagulation Physiology

A hematologic abnormality can be visible at several scales. A karyotype surveys whole chromosomes, fluorescence in situ hybridization (FISH) examines selected loci in individual cells, and nucleic-acid methods detect or quantify a chosen DNA sequence or RNA transcript. The useful result depends on the question, the specimen, and the method’s detection limit. Hemostasis follows the same principle of linked scales: a vessel response and platelet plug form first, coagulation generates enough thrombin to reinforce that plug with cross-linked fibrin, and regulatory and fibrinolytic systems confine and remove the clot.

Molecular and cytogenetic testing

Choosing a method

Specimen and question. Bone marrow aspirate commonly supplies both dividing cells and a high proportion of the abnormal clone at diagnosis. Peripheral blood may be suitable when abnormal cells circulate and is standard for many serial molecular measurements. Fixed tissue supports selected FISH assays. The laboratory verifies specimen identity, nucleic-acid quality, target abundance, assay sensitivity, and the relation between the diagnostic target and the planned follow-up assay before reporting a result.

Amplification control. PCR copies every compatible template in the reaction. Separate reagent preparation, specimen extraction, and post-amplification activities; move materials in one direction; use aerosol-resistant tips and extraction, positive, negative, and no-template controls; and apply a validated carryover-control system. Uracil-N-glycosylase can destroy uracil-containing products from prior reactions when the assay chemistry is designed for it. An internal amplification control helps separate a true target-negative specimen from inhibition or extraction failure.¹

Quantitation. Real-time PCR records fluorescence during each cycle. A lower quantification cycle means the starting specimen contained more target. A standard curve can convert cycle values to copy number; a reference gene can normalize target transcript to the amount and quality of amplifiable material. Report only within the assay’s validated measuring interval. An undetectable result requires a valid control-gene result and a stated sensitivity, because residual target below that limit may remain.

FISH patterns and limitations

FISH probes hybridize to complementary sequences in fixed nuclei. A centromere enumeration probe can assess chromosome copy number. A locus-specific probe can detect deletion or amplification. A break-apart probe places two colors on opposite sides of one gene: an intact locus gives an adjacent or fused signal, while a rearranged locus separates the colors. A dual-fusion probe places colors on the two partner genes and demonstrates their new proximity after a reciprocal translocation.

Interphase FISH works without cell division and can provide a rapid result from marrow, blood, touch preparations, or paraffin sections when the assay is validated for that material. Conventional karyotyping adds the genome-wide view and the context of the derivative chromosomes. Either method can miss a clone below its validated cutoff. Nuclear truncation in tissue, overlapping nuclei, weak or split signals, and atypical rearrangements require method-specific interpretive rules and adequate normal and abnormal controls.

Cytogenomic nomenclature

The short chromosome arm is p and the long arm is q. Regions and bands are numbered outward from the centromere. Thus, 9q34 identifies chromosome 9, long arm, region 3, band 4. A chromosome result begins with the chromosome count and sex-chromosome complement, followed by abnormalities:

• 46,XX and 46,XY describe normal chromosome counts and complements.
• 47,XY,+8 describes a male karyotype with trisomy 8.
• t(9;22)(q34;q11.2) describes a reciprocal translocation between the stated bands.
• del(5)(q31) describes a deletion involving 5q31.
• der(22) names a structurally rearranged chromosome 22 whose centromere is retained.

ISCN 2024 is the current nomenclature source and includes cytogenomic descriptions beyond these introductory forms. A laboratory report uses the current standard and its published errata for the method performed.²

Recurrent abnormalities

BCR::ABL1. The Philadelphia chromosome, t(9;22)(q34;q11.2), joins the tyrosine-kinase portion of ABL1 to BCR. The resulting protein signals continuously. The common breakpoint groups produce p210, p190, or p230 proteins. p210 is characteristic of chronic myeloid leukemia (CML); p190 is common in BCR::ABL1-positive B-lymphoblastic leukemia; p230 occurs in uncommon CML phenotypes.

Diagnosis may combine karyotype, FISH, and a transcript assay. Establishing the transcript type is essential because subsequent molecular monitoring must recognize that transcript. For the common CML transcripts, quantitative reverse-transcription PCR is reported on the BCR::ABL1 International Scale. Major molecular response is 0.1% or lower on that scale; deeper responses require both a lower ratio and enough control-gene molecules to prove the stated sensitivity. The 2025 European LeukemiaNet recommendations retain this calibrated approach and require local assay validation.³

JAK2. The JAK2 V617F variant supports a clonal myeloproliferative neoplasm in the appropriate blood-count, marrow, and clinical setting. It occurs in most polycythemia vera cases and in substantial fractions of essential thrombocythemia and primary myelofibrosis. A V617F-negative specimen with a strong polycythemia vera suspicion prompts validated JAK2 exon 12 testing. Variant allele fraction, detection limit, specimen cellularity, and possible low-level clonal hematopoiesis all affect the report’s meaning.

Acute myeloid leukemia. WHO-HAEM5 defines several AML entities by recurrent genetic lesions, including PML::RARA, RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, and RBM15::MRTFA fusions; rearrangements involving KMT2A, MECOM, or NUP98; and qualifying NPM1 or CEBPA variants. AML, myelodysplasia-related uses specified cytogenetic or molecular abnormalities within an integrated diagnosis. Morphology, immunophenotype, cytogenetics, and molecular results remain linked in the final classification.⁴

Hemostasis physiology

A localized response to vessel injury

Hemostasis joins five processes:

1. The vessel constricts and the damaged surface exposes collagen and tissue factor.
2. Platelets adhere, activate, secrete granule contents, and aggregate into a primary plug.
3. Coagulation complexes assemble on cell membranes and generate thrombin.
4. Thrombin converts fibrinogen to fibrin, and factor XIIIa cross-links the fibrin mesh.
5. Anticoagulant and fibrinolytic reactions confine the response and later clear the clot.

Primary hemostasis explains the rapid platelet plug and mucocutaneous bleeding pattern of platelet or VWF defects. Secondary hemostasis explains fibrin reinforcement and the deep-tissue bleeding pattern of severe coagulation-factor deficiency. They occur together on the activated platelet surface.

Endothelium and platelets

Intact endothelium supports flow and suppresses platelet and coagulation activation. Prostacyclin and nitric oxide inhibit platelets and dilate vessels. Surface heparan sulfate accelerates antithrombin. Tissue factor pathway inhibitor restrains tissue factor-factor VIIa activity. Thrombomodulin and the endothelial protein C receptor direct thrombin toward protein C activation. Endothelial tissue plasminogen activator supports later fibrinolysis.

Injury exposes collagen and tissue factor. Endothelial Weibel-Palade bodies release VWF. Under high shear, VWF bound to collagen captures platelet glycoprotein Ib-IX-V. Collagen receptors reinforce adhesion. Activated platelets change shape, expose negatively charged phosphatidylserine, release ADP and calcium from dense granules, and synthesize thromboxane A2. These signals recruit and activate additional platelets. Activated glycoprotein IIb/IIIa, integrin αIIbβ3, binds fibrinogen and links adjacent platelets into an aggregate.

Bernard-Soulier syndrome disrupts the Ib-IX-V adhesion receptor. Glanzmann thrombasthenia disrupts IIb/IIIa-mediated aggregation. Aspirin irreversibly blocks platelet cyclooxygenase-1 and reduces thromboxane-dependent amplification for the life of the affected platelet. The separate Qualitative Platelet Defects module owns the disease classification and aggregometry patterns.

Coagulation proteins and complexes

Most coagulation enzymes circulate as inactive zymogens. The suffix a marks an activated factor. Factors V and VIII are cofactors that accelerate their partner proteases. Tissue factor is a membrane cofactor. Factor XIIIa is a transglutaminase that cross-links fibrin.

Factors II, VII, IX, and X and proteins C, S, and Z require vitamin K-dependent gamma-carboxylation. The added carboxyl groups bind calcium, which anchors these proteins to phospholipid membranes. Warfarin or vitamin K deficiency lowers their functional activity. Liver failure can lower a broader set of hepatic procoagulants and regulators. Factor VIII is produced mainly by endothelial cells and circulates protected by VWF.

Contact system. Factor XII, prekallikrein, and high-molecular-weight kininogen initiate coagulation on negatively charged surfaces in the activated partial thromboplastin time assay. Deficiency can markedly prolong that assay while leaving clinical hemostasis intact. Factor XI deficiency differs: it can cause variable bleeding, especially after procedures in tissues with high fibrinolytic activity.

Thrombin and fibrin. Thrombin cleaves fibrinopeptides from fibrinogen, activates platelets and factors V, VIII, XI, and XIII, and produces a rapid amplification loop. Fibrin monomers polymerize by binding complementary sites on neighboring molecules. Factor XIIIa forms covalent cross-links and incorporates alpha2-antiplasmin, strengthening the clot against early lysis.

Classic and cell-based models

The classic cascade remains useful for interpreting plasma clotting tests. The prothrombin time (PT) measures the tissue factor, factor VII, and common-pathway response. The activated partial thromboplastin time (APTT) measures contact activation, factors XI, IX, and VIII, and the common pathway. Both converge at factor X, factor V, prothrombin, and fibrinogen.

Physiologic coagulation occurs on cells in three overlapping phases:⁵

1. Initiation. Tissue factor-bearing cells bind factor VIIa and generate small amounts of Xa, IXa, and thrombin.
2. Amplification. The initial thrombin activates platelets and cofactors V and VIII and supports factor XI activation.
3. Propagation. Intrinsic tenase and prothrombinase assemble on activated platelet membranes, producing the thrombin burst that forms and stabilizes fibrin.

This model explains why the tissue factor route starts hemostasis while factors VIII and IX remain essential for adequate thrombin generation. It also explains why a plasma assay can show severe contact-factor prolongation without a bleeding phenotype.

Control of coagulation

Protein S circulates in free and C4b-binding-protein-bound forms; the free fraction serves as the activated protein C cofactor. A low free protein S result during inflammation, pregnancy, or estrogen exposure may be acquired. Antithrombin deficiency can blunt the anticoagulant response to heparin, because heparin acts by accelerating antithrombin.

Fibrinolysis

Endothelial tissue plasminogen activator and urokinase-type plasminogen activator convert plasminogen to plasmin. Binding both activator and plasminogen to fibrin concentrates plasmin generation within the clot. Plasmin cleaves fibrin into fragments. Digestion of factor XIIIa-cross-linked fibrin releases D-dimer, so D-dimer records both clot formation and subsequent lysis.

Plasminogen activator inhibitor-1 inactivates free activators. Alpha2-antiplasmin rapidly neutralizes plasmin that leaves the fibrin surface. Thrombin-activatable fibrinolysis inhibitor removes exposed lysine-binding sites from partly digested fibrin and slows further plasmin formation. These controls preserve a useful clot during repair, while delayed local fibrinolysis restores vessel patency.